Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The child must be between 0 and 18 years old (any sex).
• The child must have a confirmed diagnosis of Langerhans cell histiocytosis (LCH) — a rare disease involving abnormal immune cells — proven by a laboratory test showing specific markers (CD1a and/or CD207), and must not have received any treatment for LCH before.
• The child's LCH must affect more than one part or system of the body, as confirmed by medical tests and scans.
• A parent or legal guardian must be willing and able to sign a consent form agreeing to take part, follow the treatment plan, and attend follow-up appointments (and the child may also be asked to give their agreement if old enough).

Who may not be able to join:

• Children who have another serious underlying health condition, such as a weakened immune system from birth, heart failure, kidney problems, long-term hepatitis, HIV, or who have had an organ transplant.
• Children who have had a second, separate type of cancer at any point.
• Children whose heart electrical activity test (ECG) shows a specific measurement (called QTcF) above 0.47 seconds before joining the trial.
• Children whose eye examination before joining the trial shows certain eye problems — such as a blocked vein in the eye or separation of eye tissue layers — that the doctor feels would make it unsafe to participate.
• Children whose LCH has a specific type of gene change (called a Class 3 MEK pathway mutation — a particular list of genetic alterations) (confirm with trial site if unsure whether this applies).
• Children whose parent or guardian is unwilling or unable to sign the required consent forms.

Important: Always verify eligibility with the trial site directly before applying.